Compare Match Group Inc (MTCH) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs Novartis AG — how do they compare? Match Group Inc trades at $41.46 (market cap $9.45B), while Novartis AG trades at $139.57 (market cap $262.64B). The key difference: Novartis AG is far larger — about 27.8× Match Group Inc's market cap, and Novartis AG pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| MTCH | NVS | |
|---|---|---|
Market Cap | $9.45B | $262.64B |
Sector | Media | Health |
52-Week High | $42.44 | $168.62 |
52-Week Low | $28.90 | $121.80 |
Enterprise Value | $12.41B | $303.97B |
Dividend Yield | 1.94% | 3.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $41.15, down 1.7% today, near its consensus price target of $42.50. The stock shows a bullish technical signal with support at $41 and resistance at $42. Recent earnings beat expectations in Q2 2026, with Q3 2026 results pending. Revenue stability around $3.5B and a net income margin of 20.17% reflect solid profitability, though high debt levels pose a risk. Analysts are overwhelmingly positive with 53% buy ratings and no sell recommendations.
The outlook for MTCH is cautiously optimistic, driven by product innovation at Tinder and strong cash flow growth. Investment opportunities include potential upside to the $45 high price target and dividend payments. Risks include elevated long-term debt of $3.85B and competitive pressures in the dating app market. Investors should monitor Q3 2026 earnings for confirmation of growth trends.
Novartis (NVS) stock is trading at $137.7, down 13.93% over 24 hours following negative clinical trial news. The technical outlook is bearish with support at $133 and resistance at $138. Fundamentally, the company maintains strong profitability with a 22.5% net income margin and $56.67B revenue in 2025, though recent pipeline setbacks have pressured sentiment. Analyst consensus is mixed with 24% buy ratings but 68% hold, reflecting caution amid growth uncertainties.
The investment outlook is clouded by recent trial failures, but Novartis' solid cash flow and reiterated 5-6% revenue growth guidance through 2030 provide a foundation. Key risks include pipeline execution and competitive threats, while institutional ownership trends will be critical to watch for stability signals. The stock offers value if management can navigate current headwinds effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
